Ethyl acetate extract - Hanmi Pharmaceutical
Alternative Names: Acetates; ALS-L1023; McEye; Melissa leaf ethyl acetate dried extractLatest Information Update: 27 Dec 2023
Price :
$50 *
At a glance
- Originator AngioLab Inc
- Developer AngioLab Inc; Hanmi Pharmaceutical
- Class Acetates; Eye disorder therapies; Hepatoprotectants; Herbal medicines; Obesity therapies
- Mechanism of Action Angiogenesis inhibitors; Matrix metalloproteinase inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Diabetic macular oedema; Diabetic retinopathy; Retinopathy of prematurity
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis; Wet age-related macular degeneration
- No development reported Eye disorders; Obesity
Most Recent Events
- 10 Nov 2023 Efficacy and adverse event data from a phase IIa trial in Non-alcoholic steatohepatitis presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-023)
- 26 Aug 2022 AngioLab completes a phase II trial in Non-alcoholic steatohepatitis in South Korea (PO) (NCT04342793)
- 26 Jul 2022 Ethyl acetate extract is still in phase II trials for Non-alcoholic steatohepatitis in South Korea